1[2]Yanagisaw M. Anovel potent vasoconstrictor peptide produced by vascular endothelial cells [J]. Nature, 1988, 322: 411.
2[6]Gillis JC, Markham A. Irbesatan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension [J]. Drugs, 1997, 54 (6): 885.
3[7]Ruilope L. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin Ⅱ receptor antagonist [J].J HypertensSuppl, 1997, 15 (7): S15-20.
4[8]Oparil S. Newly emerging pharmacologic differences in agniotens Ⅱ receptor blockers [J]. Am J Hypertens, 2000, 13 (1 Pt 2):18S- 24S.
